Imaging and Targeting Metastatic-Prone Breast Cancer
易转移性乳腺癌的成像和靶向治疗
基本信息
- 批准号:8634079
- 负责人:
- 金额:$ 54.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-08 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelBioluminescenceBreast Cancer ModelCell LineCellsCharacteristicsComplementary DNAData SetDetectionDevelopmentDiseaseEnzymesEvolutionGene ExpressionGenesGrowthGrowth and Development functionHumanImageLabelLactic acidLinkMalignant NeoplasmsMammary NeoplasmsMetabolicMetabolic PathwayMetabolismMolecular ProfilingMonitorMutationNeoplasm MetastasisPhenotypePhysiologic pulsePrimary NeoplasmProductionRNAReporterResearchRiskRoleSystemTechniquesTissuesTransgenic ModelTumor-DerivedWomancancer cellcellular transductionimprovedinterestknock-downlactate dehydrogenase Amagnetic resonance spectroscopic imagingmalignant breast neoplasmmortalityneoplastic cellnon-invasive monitornoveloutcome forecastprotein expressionpublic health relevanceresponsesmall hairpin RNAtumortumor growthtumor metabolismtumor microenvironmenttumor progressionvector
项目摘要
DESCRIPTION (provided by applicant): Mortality in breast cancer, the most common malignancy in women, is usually caused by metastatic disease. This application focuses on the impact of changes in lactic acid metabolism on disease evolution, progression and development of metastases. This application focuses on two components of an abnormal metabolic phenotype in breast cancer involving lactate dehydrogenase A (LDH-A) and monocarboxylate transporter 4 (MCT4), because LDH-A is a bridge between several metabolic pathways and MCT-4 is primarily involved in the export of lactate from cancer cells. We propose to show that cells and tumors with high lactate secretion and/or tissue concentrations express high levels of LDH-A and MCT4, and that they are prone to be more invasive and to develop metastases. The expression of LDH-A and MCT4 are very highly correlated with the duration of metastasis-free survival in human breast cancer, and expression of these genes is expected to be highly correlated with tumor lactate concentrations. In addition, the product of LDH-A activity (lactate) can be assessed non-invasively and quantitatively using magnetic resonance spectroscopic (MRS) imaging (MRSI). Although lactate MRSI is not a new technique, the correlation with LDH-A and MCT4 gene expression and the non-invasive monitoring of LDH-A targeted therapy using lactate MRSI is novel. This research focus is supported by our expression profile analysis of genes involved in lactate metabolism in human breast cancer (see Fig. 1, Section 3.1), and strongly supports the rationale for this proposal. Our hypotheses are: 1) tumor lactate levels can be quantitatively assessed by MRSI; 2) tumor lactate levels will reflect corresponding levels of LDH-A and MCT4 expression, 3) tumor lactate, LDH-A and MCT4 are important components of the metabolic phenotype and have a major impact on the tumor microenvironment, tumor progression and the development of metastases; and 4) LDH-A inhibition can reduce breast cancer progression and reduce the development of metastases. Our Aims are: 1) Identify the associations between LDH-A, MCT4, lactate production, and the aggressive/ metastatic tumor phenotype in different orthotopic and transgenic models of breast cancer during tumor progression; and 2) Image and monitor the effects of LDH-A silencing/knock-down and determine the effect of lactate and pHe levels on tumor growth and development of metastases.
描述(由申请人提供):乳腺癌是女性最常见的恶性肿瘤,其死亡率通常是由转移性疾病引起的。该应用重点关注乳酸代谢变化对疾病演变、进展和转移发展的影响。本申请重点关注乳腺癌异常代谢表型的两个组成部分,涉及乳酸脱氢酶 A (LDH-A) 和单羧酸转运蛋白 4 (MCT4),因为 LDH-A 是多个代谢途径之间的桥梁,而 MCT-4 主要参与癌细胞输出乳酸。我们建议证明具有高乳酸分泌和/或组织浓度的细胞和肿瘤表达高水平的LDH-A和MCT4,并且它们更容易更具侵袭性并发生转移。 LDH-A和MCT4的表达与人类乳腺癌的无转移生存期高度相关,并且这些基因的表达预计与肿瘤乳酸浓度高度相关。此外,可以使用磁共振波谱 (MRS) 成像 (MRSI) 对 LDH-A 活性产物(乳酸)进行非侵入性定量评估。尽管乳酸 MRSI 不是一项新技术,但与 LDH-A 和 MCT4 基因表达的相关性以及使用乳酸 MRSI 对 LDH-A 靶向治疗的无创监测是新颖的。这一研究重点得到了我们对人类乳腺癌乳酸代谢相关基因的表达谱分析的支持(见图 1,第 3.1 节),并强烈支持了该提议的基本原理。我们的假设是:1)可以通过 MRSI 定量评估肿瘤乳酸水平; 2)肿瘤乳酸水平将反映相应的LDH-A和MCT4表达水平,3)肿瘤乳酸、LDH-A和MCT4是代谢表型的重要组成部分,对肿瘤微环境、肿瘤进展和肿瘤发生发展有重大影响。转移; 4) LDH-A 抑制可以减少乳腺癌进展并减少转移的发展。我们的目标是: 1) 确定不同原位和转基因乳腺癌模型在肿瘤进展过程中 LDH-A、MCT4、乳酸产生和侵袭性/转移性肿瘤表型之间的关联; 2) 成像并监测 LDH-A 沉默/敲低的效果,并确定乳酸和 pHe 水平对肿瘤生长和转移发展的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald George Blasberg其他文献
Ronald George Blasberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald George Blasberg', 18)}}的其他基金
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy
图像引导 Trp-IDO/TDO-Kyn-AHR 通路抑制结合免疫治疗
- 批准号:
10405124 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别:
Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy
图像引导 Trp-IDO/TDO-Kyn-AHR 通路抑制结合免疫治疗
- 批准号:
10220621 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别:
Enhancement of T cell therapy by incorporating adjunct treatment strategies
通过结合辅助治疗策略增强 T 细胞治疗
- 批准号:
9903003 - 财政年份:2019
- 资助金额:
$ 54.98万 - 项目类别:
Imaging tumor and T cell responses to metabolic and immune modulation therapy
成像肿瘤和 T 细胞对代谢和免疫调节治疗的反应
- 批准号:
9544475 - 财政年份:2017
- 资助金额:
$ 54.98万 - 项目类别:
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
嵌合抗原受体 (CAR) T 细胞治疗中的免疫调节成像
- 批准号:
9307774 - 财政年份:2016
- 资助金额:
$ 54.98万 - 项目类别:
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
嵌合抗原受体 (CAR) T 细胞治疗中的免疫调节成像
- 批准号:
9177127 - 财政年份:2016
- 资助金额:
$ 54.98万 - 项目类别:
Imaging and Targeting Metastatic-Prone Breast Cancer
易转移性乳腺癌的成像和靶向治疗
- 批准号:
9008029 - 财政年份:2013
- 资助金额:
$ 54.98万 - 项目类别:
Imaging and Targeting Metastatic-Prone Breast Cancer
易转移性乳腺癌的成像和靶向治疗
- 批准号:
8829787 - 财政年份:2013
- 资助金额:
$ 54.98万 - 项目类别:
Imaging and Targeting Metastatic-Prone Breast Cancer
易转移性乳腺癌的成像和靶向治疗
- 批准号:
8422419 - 财政年份:2013
- 资助金额:
$ 54.98万 - 项目类别:
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival
肿瘤微环境:对 T 细胞肿瘤靶向、激活和存活的影响
- 批准号:
8468136 - 财政年份:2012
- 资助金额:
$ 54.98万 - 项目类别:
相似国自然基金
近红外二区长余辉发光复合纳米探针的构建及其生物成像应用
- 批准号:22364016
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
抗生物污染电化学发光传感器构建及在海洋环境抗生素检测中的应用研究
- 批准号:22374086
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
一维分子晶体的电化学发光波导及在单细胞内生物传感应用
- 批准号:22374078
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向多重急性心肌梗死生物标志物现场快速检测的干式免疫闭合式双极电化学发光传感技术的研究
- 批准号:32371554
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
近红外二区生物发光活体成像系统的理论设计
- 批准号:22373010
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Optical platform for functional longitudinal imaging of metabolite uptake in vivo
用于体内代谢物摄取功能纵向成像的光学平台
- 批准号:
10585764 - 财政年份:2023
- 资助金额:
$ 54.98万 - 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
- 批准号:
10434241 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别:
Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell Activity
开发增强 CAR T 细胞活性的外科药物输送系统
- 批准号:
10513306 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别:
Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell Activity
开发增强 CAR T 细胞活性的外科药物输送系统
- 批准号:
10688135 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别:
Therapy for Metastatic breast cancer based on micro RNA silencing
基于微小RNA沉默的转移性乳腺癌治疗
- 批准号:
10489811 - 财政年份:2021
- 资助金额:
$ 54.98万 - 项目类别: